Hanson Pharmaceuticals (03692) announced its 2023 results, with revenue of about 10.104 billion yuan, an increase of 7.7% year-on-year...
According to the Zhitong Finance App, Hanson Pharmaceuticals (03692) announced its 2023 results, with revenue of approximately RMB 10.104 billion, up 7.7% year on year; R&D expenditure of about RMB 2,097 billion, up 23.8% year on year; net profit of RMB 3.277.5 billion, up 26.85% year on year; basic profit of $0.55 per share, with a final dividend of HK14.22 cents per share.
Among them, the Group's sales revenue for innovative drugs and cooperative products was approximately RMB 6.865 billion, an increase of about 37.1% over the previous year, accounting for about 67.9% of total revenue. In terms of innovative research and development, the group continued to increase R&D investment to enhance independent innovation capabilities and R&D efficiency. During the reporting period, the group was approved to market an innovative drug, included in the national health insurance catalogue in the same year, and has reserves of more than 30 innovative drug projects at different stages of research and development. At the same time, the Group closely monitors cutting-edge developments in the global pharmaceutical industry, actively seizes cooperation opportunities in business development (BD), accelerates the commercialization process of the Group's innovative achievements, and continuously explores opportunities to enrich the innovative product pipeline.